Diabetes Mellitus Clinical Trial
Official title:
A Phase ½ Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells in Patients With Type 1 Diabetes Mellitus
The purpose of this study is to determine the safety and tolerability of the administration of tolerogenic dendritic cells in patients with type 1 diabetes mellitus.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of Type 1 Diabetes Mellitus - The patient can read, understand, follow the examination procedures and complete, if necessary, the required documentation - Written informed consent Exclusion Criteria: - The presence of any malignant tumor within the last 5 years - Acute or chronic diseases in the stage of decompensation - Chronic infectious diseases: HIV, viral hepatitis B, C, tuberculosis - Patients who are pregnant, breastfeeding, or fertile patients who are not using adequate contraceptive methods - Chronic and protracted mental disorders, all diseases with the presence of the syndrome of dependence on alcohol, drugs and psychoactive substances, any other condition that makes the patient unable to understand the nature, extent and possible consequences of the study or, in the opinion of the researcher, prevents the patient from observing and performing protocol - Patients are unable or unwilling to give written informed consent and / or follow research procedures - Any other medical condition that, in the opinion of the investigator, may be associated with an increased risk to the patient or may affect the outcome or evaluation of the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The glucose concentration in blood | To assess the glucose concentration in blood | 1 month | |
Primary | The glycated hemoglobin concentration | To assess the ß-cell function measured by the glycated hemoglobin in blood | 1 month | |
Primary | The C-peptide level in blood | To assess the ß-cell function measured by the C-peptide level | 1 month | |
Primary | The glucose concentration in blood | To assess the glucose concentration in blood | 6 months | |
Primary | The glycated hemoglobin concentration | To assess the ß-cell function measured by the glycated hemoglobin in blood | 6 months | |
Primary | The C-peptide level in blood | To assess the ß-cell function measured by the C-peptide level | 6 months | |
Primary | The glucose concentration in blood | To assess the glucose concentration in blood | 1 year | |
Primary | The glycated hemoglobin concentration | To assess the ß-cell function measured by the glycated hemoglobin in blood | 1 year | |
Primary | The C-peptide level in blood | To assess the ß-cell function measured by the C-peptide level | 1 year | |
Primary | Autoantigen specific T cell count | To determine the autoantigen specific T cell count using the flow cytometry | 1 month | |
Primary | Autoantigen specific T cell count | To determine the autoantigen specific T cell count using the flow cytometry | 6 months | |
Primary | Autoantigen specific T cell count | To determine the autoantigen specific T cell count using the flow cytometry | 1 year | |
Primary | Adverse effects associated with the therapy | Determination of adverse effects associated with the therapy | 1 month | |
Primary | Adverse effects associated with the therapy | Determination of adverse effects associated with the therapy | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Recruiting |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Recruiting |
NCT03462420 -
Physiotherapy Program for Managing Adhesive Capsulitis in Patients With Diabetes
|
N/A |